Effect of Lipid Abnormality on CKD Progression from Moderate to Severe Stage: Application of Flexible Parametric Proportional-Hazards and Proportional-Odds Models

Background: Lipid disorders are a well-documented risk factor for chronic kidney disease (CKD), but the impact of lipid abnormalities in the progression of the disease remains mixed. Objectives: The current study aimed to extend the existing knowledge about the effect of lipid disorders in disease progression from moderate to severe stage using Flexible parametric survival models. Methods: This retrospective cohort study included 308 moderate CKD patients who received the nephrologist follow-up visits at the nephrology clinic, Ilam (Iran), from 2012 to 2019. The survival time was determined based on the time medically diagnosed with moderate stages (GFR = 59 - 55 mL/min per 1.73 m2) to the time of progression to the severe stage (GFR = 29 - 25 mL/min per 1.73 m2) hazard using flexible parametric survival models. Results: In univariate analysis, high levels of TG, LDL, and cholesterol were important risk factors which affect the CKD progression. The hazard of patients with TG > 200 mg/dL was 1.69 times higher than patients with desirable TG levels (P = 0.09). Moreover, for patients with LDL > 160 mg/dL, the hazard was 2.12 times higher than patients with desirable LDL levels (P = 0.01). The hazard of patients with total cholesterol levels > 240 mg/dL was 2.10 times higher than patients with desirable cholesterol levels (P = 0.003). The adjusted model was shown to better fit the PH model. Cholesterol levels > 240 mg/dL remains a significant risk factor for CKD progression (P = 0.03). Conclusions: Effective treatment programs should pay closer attention to screening and treatment of hyperlipidemia in patients diagnosed with moderate CKD.

[1]  A. Žák,et al.  Dyslipidemia in patients with chronic kidney disease: etiology and management. , 2020, Vnitrni lekarstvi.

[2]  H. Argani,et al.  Protection of renal damage by HMG-CoA inhibitors: A comparative study between atorvastatin and rosuvastatin , 2020, Iranian journal of basic medical sciences.

[3]  M. Hesaraki,et al.  Prevalence of Chronic Kidney Disease in Iranian General Population: A Meta‐Analysis and Systematic Review , 2018, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[4]  F. Kronenberg HDL in CKD-The Devil Is in the Detail. , 2018, Journal of the American Society of Nephrology : JASN.

[5]  B. Afşar,et al.  Disorders of Lipid Metabolism in Chronic Kidney Disease , 2018, Blood Purification.

[6]  Lala Septem Riza,et al.  Detection of kidney disease using various intelligent classifiers , 2017, 2017 3rd International Conference on Science in Information Technology (ICSITech).

[7]  N. A. Tutkun,et al.  Flexible parametric survival models: An application to gastric cancer data , 2017 .

[8]  Lisa R Tannock,et al.  Dyslipidemia in patients with chronic kidney disease , 2017, Reviews in Endocrine and Metabolic Disorders.

[9]  L. Orlić,et al.  Dyslipidemia in patients with chronic kidney disease: etiology and management , 2017, International journal of nephrology and renovascular disease.

[10]  D. Santoro,et al.  Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease , 2016, Journal of clinical & translational endocrinology.

[11]  M. Mansournia,et al.  Flexible parametric survival models built on age-specific antimüllerian hormone percentiles are better predictors of menopause , 2016, Menopause.

[12]  W. Kang,et al.  Human papillomavirus genotyping as a reliable prognostic marker of recurrence after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia (CIN2-3) especially in postmenopausal women , 2016, Menopause.

[13]  N. Baral,et al.  Thyroid dysfunction and dyslipidemia in chronic kidney disease patients , 2015, BMC Endocrine Disorders.

[14]  Mostafa HOSSEINI,et al.  A Comparison between Accelerated Failure-time and Cox Proportional Hazard Models in Analyzing the Survival of Gastric Cancer Patients , 2015, Iranian journal of public health.

[15]  Lisa R Tannock Dyslipidemia in Chronic Kidney Disease , 2015 .

[16]  Akhilesh Rao,et al.  Lipid abnormalities in kidney disease and management strategies. , 2015, World journal of nephrology.

[17]  M. Kuo,et al.  Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease , 2013, PloS one.

[18]  M. Tonelli,et al.  Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease , 2012, Annals of Internal Medicine.

[19]  Paul C. Lambert,et al.  Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model , 2011 .

[20]  Paul C. Lambert,et al.  Further Development of Flexible Parametric Models for Survival Analysis , 2009 .

[21]  F. Azizi,et al.  High prevalence of chronic kidney disease in Iran: a large population-based study , 2009, BMC public health.

[22]  A. Khwaja,et al.  The management of CKD: a look into the future. , 2007, Kidney international.

[23]  N. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. , 2006, American journal of physiology. Renal physiology.

[24]  A. Cases,et al.  Dyslipidemia and the progression of renal disease in chronic renal failure patients. , 2005, Kidney international. Supplement.

[25]  H. Bloomfield,et al.  Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[27]  J. Buring,et al.  Cholesterol and the risk of renal dysfunction in apparently healthy men. , 2003, Journal of the American Society of Nephrology : JASN.

[28]  R. Bigazzi,et al.  A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  P. Royston,et al.  Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.

[30]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[31]  M. Ravid,et al.  Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. , 1998, Archives of internal medicine.

[32]  H. Wedel,et al.  Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[34]  V. Manninen,et al.  Effects of hypertension and dyslipidemia on the decline in renal function. , 1995, Hypertension.

[35]  A. Krolewski,et al.  Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. , 1994, Kidney international. Supplement.

[36]  J. Mustonen,et al.  Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.